1. Home
  2. RNAC vs STXS Comparison

RNAC vs STXS Comparison

Compare RNAC & STXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cartesian Therapeutics Inc.

RNAC

Cartesian Therapeutics Inc.

HOLD

Current Price

$7.79

Market Cap

217.1M

Sector

Health Care

ML Signal

HOLD

Logo Stereotaxis Inc.

STXS

Stereotaxis Inc.

HOLD

Current Price

$2.23

Market Cap

201.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RNAC
STXS
Founded
2007
1990
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
217.1M
201.6M
IPO Year
2016
2004

Fundamental Metrics

Financial Performance
Metric
RNAC
STXS
Price
$7.79
$2.23
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
5
2
Target Price
$38.80
$4.00
AVG Volume (30 Days)
117.8K
410.7K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$38,913,000.00
$29,346,617.00
Revenue This Year
N/A
$24.21
Revenue Next Year
N/A
$29.83
P/E Ratio
N/A
N/A
Revenue Growth
49.64
N/A
52 Week Low
$5.98
$1.54
52 Week High
$18.80
$3.59

Technical Indicators

Market Signals
Indicator
RNAC
STXS
Relative Strength Index (RSI) 59.43 51.12
Support Level $6.20 $2.04
Resistance Level $7.99 $2.49
Average True Range (ATR) 0.62 0.11
MACD 0.12 0.03
Stochastic Oscillator 74.89 89.47

Price Performance

Historical Comparison
RNAC
STXS

About RNAC Cartesian Therapeutics Inc.

Cartesian Therapeutics Inc is a clinical-stage biopharmaceutical company. The company uses its ImmTOR immune tolerance platform, which is designed to give rise to antigen-specific immunity, mitigating unwanted immune responses. The company leverages its proprietary technology and manufacturing platform to introduce one or more mRNA molecules into cells to enhance their function.

About STXS Stereotaxis Inc.

Stereotaxis Inc is engaged in robotic technologies designed to enhance the treatment of arrhythmias and perform endovascular procedures. The company's mission is the discovery, development, and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. The company's revenue generation is derived from the streams of Systems; Disposables, Royalty; and Sublease, of which a majority of revenue is generated from the Disposables, service, and accessories stream.

Share on Social Networks: